 | | Vol. 14.06 – 14 February, 2023 |
| |
|
|
| Researchers found that adults with chronic immune thrombocytopenia had increased polyfunctional, terminally differentiated effector memory (TEMRA) CD8+ T cells expressing intracellular interferon-g, tumor necrosis factor-a, and Granzyme B defining them as TEMRA cells.
[Blood] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists evaluated 1116 FDA-approved compounds in primary KMT2Ar infant acute lymphoblastic leukemia specimens and identified sensitivity to proteasome inhibition.
[Nature Communications] |
|
|
|
| Expression of various Cre recombinases led to polyclonal expansion of FLT3ITD/ITD progenitor cells, induction of a differentiation block, and activation of Myc-dependent gene expression programs.
[Leukemia] |
|
|
|
| Scientists showed that targeting mitochondrial fusion was a new vulnerability of AML cells when assayed in patient-derived xenograft models.
[Leukemia] |
|
|
|
| Investigators tested the hypothesis that ischemic vascular repair in aging by Ang-(1–7) involved attenuation of myelopoietic potential in the bone marrow and decreased mobilization of inflammatory cells.
[Scientific Reports] |
|
|
|
| Researchers identified 12 up-regulated and 192 down-regulated genes in leukemic stem cells of AML compared to normal bone marrow-derived HSCs.
[Scientific Reports] |
| |
|
|
| Investigators suggested that fludarabine/busulfan was associated with better outcomes in reduced intensity conditioning and myeloablative conditioning in myelofibrosis.
[Haematologica] |
|
|
|
| Scientists reported on a planned pooled analysis of five multi-center clinical trials, featuring 105 patients with hematologic malignancies or sickle cell hemoglobinopathy who underwent omidubicel transplantation at 26 academic transplant centers worldwide.
[Transplantation And Cellular Therapy] |
|
|
|
| Researchers analyzed the gene mutations and copy number alterations in younger myelodysplastic syndrome patients using next-generation sequencing, targeting 68 genes that were recurrently mutated in myeloid malignancies, to investigate the correlation between their genetic alterations and clinical outcomes.
[Scientific Reports] |
|
|
|
|
| The authors provide evidence for interactions between chronic myeloid leukemia (CML) cells and the immune microenvironment to identify targetable therapeutic vulnerabilities and describe what is known about the role of immune regulation in treatment-free remission.
[Current Hematologic Malignancy Reports] |
|
|
|
|
| Seres Therapeutics, Inc. announced that enrollment in Cohort 2 in its SER-155 Phase Ib study was underway. SER-155 was designed to reduce gastrointestinal infections, bloodstream infections, and graft versus host disease in individuals undergoing allogeneic hematopoietic stem cell transplantation.
[Seres Therapeutics, Inc.] |
|
|
|
|
| February 22 – 23, 2023
Boston, Massachusetts, United States |
|
|
|
|
|
| | Johns Hopkins University – Baltimore, Maryland, United States |
|
|
|
| | Loughborough University – Leicestershire, England, United Kingdom |
|
|
|
| | University of Birmingham – Birmingham, England, United Kingdom |
|
|
|
| | Duke University – Durham, North Carolina, United States |
|
|
|
| | Hebrew University of Jerusalem – Jerusalem, Israel |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
